- Advertise
- About OncLive
- Editorial Board
- CancerNetwork.com
- CGTlive.com
- CureToday.com
- OncNursingNews.com
- TargetedOnc.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Anasetti Discusses the Trade-offs of BMT and PBSC
December 12th 2011, 2:15pm
ASH Annual Meeting and Exposition
Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC
Novel Agent Targeting the B-Cell Receptor Shows Efficacy, Without Myelosuppression, in Chronic Lymphocytic Leukemia
December 12th 2011, 11:19am
ASH Annual Meeting and Exposition
First drug targeting Bruton's tyrosine kinase (Btk) produced high rates of remission in patients with CLL.
Chemotherapy Alone Increases Overall Survival for Early-stage Hodgkin Lymphoma
December 12th 2011, 10:22am
ASH Annual Meeting and Exposition
Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.
Burden of Morbidity Reported for Long-term Survivors of Hematopoietic Cell Transplantation
December 12th 2011, 9:36am
ASH Annual Meeting and Exposition
Bone Marrow Transplant Survivor Study analysis suggests long-term survivors of HCT have high risk of chronic psychological, and physical health conditions
Dr. Sehn Discusses the Efficacy of the CD20 Agent GA101
December 11th 2011, 1:37pm
ASH Annual Meeting and Exposition
Dr. Laurie Sehn from the British Columbia Cancer Agency Discusses the Efficacy of the CD20 Agent GA101
Minimal Dosing Strategy With Gemtuzumab Ozogamicin Improves Survival in Older Patients With Acute Myeloid Leukemia
December 11th 2011, 10:10am
ASH Annual Meeting and Exposition
Adding gemtuzumab to chemotherapy improved event-free and OS of newly diagnosed patients with acute myeloid leukemia.
Peripheral Blood Stem Cell (PBSC) Transplants Increase the Incidence of Graft-Versus-Host Disease (GVHD)
December 11th 2011, 9:39am
ASH Annual Meeting and Exposition
Study finds that peripheral blood stem cell (PBSC) transplants increase the incidence of graft-versus-host disease (GVHD).
Dr. Kochenderfer Discusses the B-cell Antigen CD19
December 10th 2011, 2:08pm
ASH Annual Meeting and Exposition
Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19
Dr. Feldman Discusses the Difficulties of Rare Lymphomas
December 10th 2011, 12:17pm
ASH Annual Meeting and Exposition
Dr. Tatyana Feldman from John Theurer Cancer Center Discusses the Difficulties of Rare Lymphomas
Bevacizumab Plus Trastuzumab and Docetaxel Improves Progression-Free Survival
December 9th 2011, 4:16pm
San Antonio Breast Cancer Symposium
A study of bevacizumab in women with HER2-positive metastatic breast cancer demonstrated that combining the drug with standard therapy improves PFS.
Photos From the 2011 San Antonio Breast Cancer Symposium
December 9th 2011, 3:50pm
San Antonio Breast Cancer Symposium
A collection of photos from the 34th annual SABCS at the Henry B. Gonzalez Convention Center in San Antonio, TX, from December 6-10, 2011.
Breast Cancer Survivors Who Are Mutation Carriers Are at Increased Risk of Cancer in Other Breast
December 9th 2011, 2:32pm
San Antonio Breast Cancer Symposium
Carriers of the BRCA1 or BRCA2 mutation are at greater risk for developing a new primary tumor in the contralateral breast compared with noncarriers.
Dr. Baselga Discusses the CLEOPATRA Pertuzumab Trial
December 9th 2011, 2:11pm
San Antonio Breast Cancer Symposium
Dr. José Baselga from Massachusetts General Hospital Discusses the CLEOPATRA Pertuzumab Trial
Hispanic/Latina Women at Greater Risk of Dying From Breast Cancer Than Non-Hispanic Whites
December 9th 2011, 12:16pm
San Antonio Breast Cancer Symposium
Tumor-related factors that lead to chemotherapy resistance in Hispanic women make them more likely to die from breast cancer than non-Hispanic whites.
Dr. Tripathy on the AVEREL Bevacizumab Trial Results
December 9th 2011, 10:20am
San Antonio Breast Cancer Symposium
Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses the AVEREL Bevacizumab Trial Results
Dual Therapy With Pertuzumab Slows Advanced Breast Cancer
December 9th 2011, 8:07am
San Antonio Breast Cancer Symposium
The CLEOPATRA trial marks the first time that dual inhibitors have demonstrated value in the treatment of HER2-positive metastatic breast cancer.
Dr. Hortobagyi Discusses the BOLERO-2 Everolimus Trial
December 8th 2011, 4:32pm
San Antonio Breast Cancer Symposium
Dr. Gabriel Hortobagyi from the MD Anderson Cancer Center Discusses the BOLERO-2 Trial
Exemestane Plus Everolimus New Standard of Care for Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer
December 8th 2011, 2:41pm
San Antonio Breast Cancer Symposium
The BOLERO-2 trial suggests that adding everolimus to hormonal therapy can overcome resistance in patients whose disease progressed.
Obese Patients With HER2-Positive Breast Cancer Have Worse Outcomes but Trastuzumab Equalizes Weight Differences
December 8th 2011, 11:42am
San Antonio Breast Cancer Symposium
A large study of HER2+ breast cancer patients shows that obese patients had worse outcomes than normal weight or overweight patients.
Dr. Perez Discusses the CLEOPATRA Pertuzumab Trial
December 8th 2011, 9:34am
San Antonio Breast Cancer Symposium
Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses the CLEOPATRA Pertuzumab Trial